Table 2:
Calculated binding free energy of notable miniprotein therapeutic candidates with wild-type and N501Y spike proteins.
| Protein | LCB1 | LCB3 | CTC-445.2 |
|---|---|---|---|
| Experimental | 0.50a | 0.82a | 21b |
| c | −83.0 | −85.6 | −75.3 |
| d | −58.9 | −58.7 | −63.2 |
| e | −24.0 | −26.9 | −12.0 |
| f | −12.8 | −12.5 | −10.5 |
| g | −12.3 | −13.0 | −10.2 |
| h | −5.9 | −5.9 | −7.1 |
| i | 6.4 | 7.1 | 3.2 |
| Predicted fold Change of j | 43,000 | 154,000 | 200 |
| Predicted k | 21 | 126 | 4.2 |
Estimated values for miniproteins obtained from Cao et al. BLI experiments.7
Reported value against wild-type spike protein.50
Directly calculated binding free energy of system with the given protein and the wild-type spike protein without empirical correction.
Directly calculated binding free energy of system with the given protein and the N501Y spike protein without empirical correction.
Difference between wild-type and N501Y spike binding affinities for given protein.
Experimental binding affinity converted to Gibbs binding free energy: .
Calculated binding free energy of the protein/wild-type spike system (corrected from the directly calculated binding free energy ) using Eq. (1).
Calculated binding free energy of the protein/N501Y spike system (corrected from the directly calculated binding free energy ) using Eq. (1).
Difference between wild-type and N501Y spike corrected binding affinities for given protein: .
Predicted fold change of Kd (from the binding affinity of given protein with wild-type spike to that with the N501Y mutant) converted from .
Predicted for given protein binding with the N501Y spike using the original for wild-type spike and the predicted fold change.